Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2
Latest Information Update: 22 Jul 2026
At a glance
- Drugs GSK 4069327A (Primary)
- Indications Shigella infections
- Focus Therapeutic Use
- Acronyms S4V03
- Sponsors LimmaTech Biologics
Most Recent Events
- 13 Apr 2026 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2026 Planned End Date changed from 1 Jul 2026 to 1 Sep 2026.
- 09 Feb 2026 Planned primary completion date changed from 1 Feb 2026 to 1 Apr 2026.